Novo Nordisk shares jumped 10% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge over rival Eli Lilly in the fast-evolving market for obesity drugs.
Source :- Markets-Economic Times Read More
